- $755M pre-tax acquired IPR&D charge associated with the Actio Biosciences acquisition.
- Estimated unfavorable impact of ~$11.00 on both Q3 2026 GAAP and non-GAAP EPS.
- The charge is non-tax deductible and directly impacts headline quarterly earnings.
?? Negative AI Sentiment (-4.0 / 10)